Kairos Pharma Announces Positive Interim Results from Phase 2 Trial of ENV105 in Advanced Prostate Cancer, Set to Present at ESMO 2025

Reuters

2025/10/07

<a href="https://laohu8.com/S/KAPA">Kairos Pharma</a> Announces Positive Interim Results from Phase 2 Trial of ENV105 in Advanced Prostate Cancer, Set to Present at ESMO 2025

Kairos Pharma Ltd. has announced that it will present data from a Phase 2 clinical trial evaluating the safety and efficacy of apalutamide in combination with carotuximab (ENV105) in patients with advanced, castration-resistant prostate cancer (mCRPC) at the European Society for Medical Oncology (ESMO) Congress, scheduled to take place in Berlin, Germany, from October 17-21, 2025. The ongoing randomized trial is enrolling 100 men with mCRPC who have progressed on prior hormone therapies, with participants receiving apalutamide either with or without ENV105. Interim results from the study will be highlighted during the presentation, focusing on preliminary safety and clinical activity. Further details about the trial can be found at https://clinicaltrials.gov/study/NCT05534646.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007913966) on October 07, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2573952440"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573952440\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573952440?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-07 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573952440","market":"us","top_or_hot":-1,"title":"Kairos Pharma Announces Positive Interim Results from Phase 2 Trial of ENV105 in Advanced Prostate Cancer, Set to Present at ESMO 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KAPA\">Kairos Pharma</a> Announces Positive Interim Results from Phase 2 Trial of ENV105 in Advanced Prostate Cancer, Set to Present at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kairos Pharma Ltd. has announced that it will present data from a Phase 2 clinical trial evaluating the safety and efficacy of apalutamide in combination with carotuximab (ENV105) in patients with advanced, castration-resistant prostate cancer (mCRPC) at the European Society for Medical Oncology (ESMO) Congress, scheduled to take place in Berlin, Germany, from October 17-21, 2025. The ongoing randomized trial is enrolling 100 men with mCRPC who have progressed on prior hormone therapies, with participants receiving apalutamide either with or without ENV105. Interim results from the study will be highlighted during the presentation, focusing on preliminary safety and clinical activity. Further details about the trial can be found at https://clinicaltrials.gov/study/NCT05534646.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007913966) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kairos Pharma Announces Positive Interim Results from Phase 2 Trial of ENV105 in Advanced Prostate Cancer, Set to Present at ESMO 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKairos Pharma Announces Positive Interim Results from Phase 2 Trial of ENV105 in Advanced Prostate Cancer, Set to Present at ESMO 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-07 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KAPA\">Kairos Pharma</a> Announces Positive Interim Results from Phase 2 Trial of ENV105 in Advanced Prostate Cancer, Set to Present at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kairos Pharma Ltd. has announced that it will present data from a Phase 2 clinical trial evaluating the safety and efficacy of apalutamide in combination with carotuximab (ENV105) in patients with advanced, castration-resistant prostate cancer (mCRPC) at the European Society for Medical Oncology (ESMO) Congress, scheduled to take place in Berlin, Germany, from October 17-21, 2025. The ongoing randomized trial is enrolling 100 men with mCRPC who have progressed on prior hormone therapies, with participants receiving apalutamide either with or without ENV105. Interim results from the study will be highlighted during the presentation, focusing on preliminary safety and clinical activity. Further details about the trial can be found at https://clinicaltrials.gov/study/NCT05534646.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007913966) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KAPA","symbol_name":"Kairos Pharma, Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL71qk7t:1","article_id":"2573952440","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573952440","pubTimestamp":1759838431,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kairos Pharma Announces Positive Interim Results from Phase 2 Trial of ENV105 in Advanced Prostate Cancer, Set to Present at ESMO 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire  on October 07, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KAPA":"Kairos Pharma, Ltd.","BK4139":"生物科技"},"translate_title":"Kairos Pharma宣布ENV105治疗晚期前列腺癌2期试验的积极中期结果，将于ESMO 2025上公布","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KAPA":0.9},"content_text":"Kairos Pharma Announces Positive Interim Results from Phase 2 Trial of ENV105 in Advanced Prostate Cancer, Set to Present at ESMO 2025\n    \n\n        Kairos Pharma Ltd. has announced that it will present data from a Phase 2 clinical trial evaluating the safety and efficacy of apalutamide in combination with carotuximab (ENV105) in patients with advanced, castration-resistant prostate cancer (mCRPC) at the European Society for Medical Oncology (ESMO) Congress, scheduled to take place in Berlin, Germany, from October 17-21, 2025. The ongoing randomized trial is enrolling 100 men with mCRPC who have progressed on prior hormone therapies, with participants receiving apalutamide either with or without ENV105. Interim results from the study will be highlighted during the presentation, focusing on preliminary safety and clinical activity. Further details about the trial can be found at https://clinicaltrials.gov/study/NCT05534646.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007913966) on October 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}